Author

F. S. Wehweck

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 5 Pathology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 6 Organism:human· 6 Approach:statistical model· 6 Research Focus:differential expression· 4 Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Research Focus:cell type annotation· 1 Research Focus:gene regulatory network inference· 1

Frequent Co-Authors

F. Cidre-Aranaz· 6 shared L. Romero-Perez· 6 shared M. F. Orth· 6 shared T. G. P. Grunewald· 6 shared T. Kirchner· 6 shared A. Marchetto· 5 shared J. Li· 5 shared J. Musa· 5 shared

Activity by Year

2018-2021 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

6 shared papersCancer Biology

F. Cidre-Aranaz

Mutual co-authors in cluster

Author profile →

6 papers

Recent·Most cited

Translational evidence for RRM2 as a prognostic biomarker and therapeutic target in Ewing sarcoma

S. Ohmura, A. Marchetto, M. F. Orth, J. Li, S. Jabar, A. Ranft, E. Vinca, K. Ceranski, M. J. Carreno-Gonzalez, L. Romero-Perez, F. S. Wehweck, J. Musa, F. Bestvater, M. M. L. Knott, T. L. B. Hoelting, , T. G. P. Grunewald

This study identifies RRM2 as a prognostic biomarker and therapeutic target in Ewing sarcoma, showing its overexpression correlates with poor survival and that its inhibition reduces tumor growth and overcomes chemoresistance.

bioRxiv · Mar 4, 2021Cancer Biology

Oncogenic hijacking of a developmental transcription factor evokes therapeutic vulnerability for ROS-induction in Ewing sarcoma

A. Marchetto, S. Ohmura, M. F. Orth, J. Li, F. S. Wehweck, M. M. L. Knott, S. Stein, D. Saucier, C. Arrigoni, J. S. Gerke, M. C. Baldauf, J. Musa, M. Dallmayer, T. L. B. Hoelting, M. Moretti, , T. G. P. Grunewald

The paper identifies SOX6 as a therapeutic target in Ewing sarcoma by showing its role in elevating ROS levels, making the disease vulnerable to ROS-inducing drugs.

bioRxiv · Mar 14, 2019Cancer Biology

Expression patterns of PD-L1 and PD-1 provide rationales for immune checkpoint inhibition in soft tissue sarcomas

M. F. Orth, V. L. Buecklein, E. Kampmann, M. Subklewe, E. Noessner, F. Cidre-Aranaz, L. Romero-Perez, F. S. Wehweck, L. Lindner, R. Issels, T. Kirchner, A. Altendorf-Hofmann, T. G. P. Grunewald, T. Knoesel

This study examines PD-L1 and PD-1 expression in soft tissue sarcomas and finds associations with TILs and poor clinical outcomes, supporting immune checkpoint inhibition in PD-L1-positive cases.

bioRxiv · Mar 8, 2019 · PreprintCancer Biology

Biomarker-based outcome prediction in prostate adenocarcinoma depends on the TMPRSS2-ERG status

J. S. Gerke, M. F. Orth, Y. Tolkach, L. Romero-Perez, F. S. Wehweck, S. Stein, J. Musa, M. M. L. Knott, T. L. B. Hoelting, J. Li, G. Sannino, A. Marchetto, S. Ohmura, F. Cidre-Aranaz, M. Mueller-Nurasyid, , T. G. P. Grunewald

This study identifies subtype-specific prognostic biomarkers in prostate adenocarcinoma, showing that their prognostic value depends on TMPRSS2-ERG fusion status.

bioRxiv · Feb 10, 2019Cancer Biology

SOX2 expression identifies Ewing sarcoma patients with high risk for tumor relapse and poor survival

G. Sannino, A. Marchetto, A. Ranft, S. Jabar, C. Zacherl, R. Alba-Rubio, S. Stein, F. S. Wehweck, M. M. Kiran, T. L. B. Hoelting, J. Musa, L. Romero-Perez, F. Cidre-Aranaz, M. M. L. Knott, J. Li, , T. G. P. Grunewald

bioRxiv · Dec 17, 2018Pathology

Targeting the CALCB/RAMP1-axis inhibits growth of Ewing sarcoma

M. Dallmayer, J. Li, S. Ohmura, R. Alba-Rubio, M. C. Baldauf, T. L. B. Hoelting, J. Musa, M. M. L. Knott, S. Stein, F. Cidre-Aranaz, F. S. Wehweck, L. Romero-Perez, J. S. Gerke, M. F. Orth, A. Marchetto, , T. G. P. Grunewald

This study identifies CALCB as a direct EWSR1-FLI1 target in Ewing sarcoma and shows that targeting the CALCB/RAMP1-axis inhibits tumor growth.

bioRxiv · Dec 8, 2018Cancer Biology